Pages that link to "Item:Q70258"

The following pages link to Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer (Q70258):

Displaying 42 items.

• Bias induced by adaptive dose-finding designs (Q5861424) (← links)
• Target toxicity design for phase I dose-finding (Q5880075) (← links)
• A system for determining maximum tolerated dose in clinical trial (Q5880093) (← links)
• PA‐CRM: A continuous reassessment method for pediatric phase I oncology trials with concurrent adult trials (Q6047779) (← links)
• DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses (Q6068878) (← links)
• A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes (Q6076490) (← links)
• Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics (Q6079344) (← links)
• Performance Measures in Dose‐Finding Experiments (Q6085864) (← links)
• Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information (Q6085905) (← links)
• A continual reassessment method without undue risk of toxicity (Q6171847) (← links)
• Statistical frameworks for oncology dose-finding designs with late-onset toxicities: a review (Q6577811) (← links)
• DROID: dose-ranging approach to optimizing dose in oncology drug development (Q6589229) (← links)
• A simulation-free approach to assessing the performance of the continual reassessment method (Q6617412) (← links)
• Fractional accumulative calibration-free odds (f-aCFO) design for delayed toxicity in phase I clinical trials (Q6618310) (← links)
• REDOMA: Bayesian random-effects dose-optimization meta-analysis using spike-and-slab priors (Q6618357) (← links)
• Comparative review of novel model-assisted designs for phase I/II clinical trials (Q6625482) (← links)
• CRM and partial order CRM with adaptive rescaling for dose-finding in immunotherapy trials with a continuous outcome (Q6625779) (← links)
• A Bayesian design for phase I cancer therapeutic vaccine trials (Q6625928) (← links)
• A nonparametric Bayesian method for dose finding in drug combinations cancer trials (Q6626759) (← links)
• BIPSE: a biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpoint (Q6626777) (← links)
• A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies (Q6627253) (← links)
• Incorporating patient-reported outcomes in dose-finding clinical trials (Q6627303) (← links)
• A novel approach for propensity score matching and stratification for multiple treatments: application to an electronic health record-derived study (Q6627427) (← links)
• Improving safety of the continual reassessment method via a modified allocation rule (Q6627502) (← links)
• A machine learning compatible method for ordinal propensity score stratification and matching (Q6627666) (← links)
• Consistency of the when the curve is not monotone and its application to the POCRM (Q6627746) (← links)
• Change-point joint model for identification of plateau of activity in early phase trials (Q6627755) (← links)
• Early phase dose-finding trials in virology (Q6627882) (← links)
• Seamless phase I/II design for novel anticancer agents with competing disease progression (Q6627954) (← links)
• Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens (Q6628011) (← links)
• Early completion of phase I cancer clinical trials with Bayesian optimal interval design (Q6628100) (← links)
• TITE-BOIN12: a Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy (Q6628336) (← links)
• A straightforward meta-analysis approach for oncology phase I dose-finding studies (Q6628513) (← links)
• Extending the continual reassessment method to accommodate step-up dosing in phase I trials (Q6628516) (← links)
• Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies (Q6629385) (← links)
• Comment on: ``Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies'' (Q6629388) (← links)
• Comment on: ``Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies'' (Q6629389) (← links)
• Rejoinder: ``Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies'' (Q6629390) (← links)
• A Bayesian time-to-event pharmacokinetic model for phase I dose-escalation trials with multiple schedules (Q6629855) (← links)
• An extended Bayesian semi-mechanistic dose-finding design for phase I oncology trials using pharmacokinetic and pharmacodynamic information (Q6630315) (← links)
• Bayesian optimization design for finding a maximum tolerated dose combination in phase I clinical trials (Q6637076) (← links)
• Dual-agent dose-finding in phase I clinical trial -- an extension of rapid enrollment design (Q6652600) (← links)